Skip to Content

UK Edition. Click here for US version.

COZAAR 12.5 MG FILM COATED TABLETS

Active substance(s): LOSARTAN POTASSIUM

PDF options:  View Fullscreen   Download PDF

PDF Transcript

XXXXXXX/XX-X

6560

Package leaflet: Information for the user

Cozaar® 12.5 mg
film‑coated tablets
Cozaar® 25 mg
film‑coated tablets
Cozaar® 50 mg
film‑coated tablets
Cozaar® 100 mg
film‑coated tablets

Black

Technical Info

Profile

Losartan potassium

Read all of this leaflet carefully before you
start taking this medicine because it contains
important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your
doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them,
even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor,
pharmacist, or nurse. This includes any possible
side effects not listed in this leaflet. See section 4.
What is in this leaflet
1. What COZAAR is and what it is used for
2. What you need to know before you take COZAAR
3. How to take COZAAR
4. Possible side effects
5. How to store COZAAR
6. Contents of the pack and other information

AMS Blue Braille Grid Version: 38.0 - 24-11-17

For Position Only

Profile:
Profile Revision:
Profile Revision Date:
Dimensions (mm):

BG148x520_260
7
050708
148 x 520mm

1. What COZAAR is and what it is used for
Losartan (COZAAR) belongs to a group of medicines
known as angiotensin‑II receptor antagonists.
Angiotensin‑II is a substance produced in the
body which binds to receptors in blood vessels,
causing them to tighten. This results in an increase
in blood pressure. Losartan prevents the binding
of angiotensin‑II to these receptors, causing the
blood vessels to relax which in turn lowers the blood
pressure. Losartan slows the decrease of kidney
function in patients with high blood pressure
and type 2 diabetes.
COZAAR is used
• to treat patients with high blood pressure
(hypertension) in adults and in children and
adolescents 6 - 18 years of age.
• to protect the kidney in hypertensive type 2
diabetic patients with laboratory evidence of
impaired renal function and proteinuria ≥ 0.5 g
per day (a condition in which urine contains
an abnormal amount of protein).
• to treat patients with chronic heart failure
when therapy with specific medicines called
angiotensin‑converting‑enzyme inhibitors
(ACE inhibitors, medicine used to lower high
blood pressure) is not considered suitable
by your doctor. If your heart failure has been
stabilised with an ACE inhibitor you should not
be switched to losartan.
• in patients with high blood pressure and
a thickening of the left ventricle, COZAAR has
been shown to decrease the risk of stroke
(“LIFE indication”).
2. What you need to know before you take
COZAAR
Do not take COZAAR:
• if you are allergic to losartan or to any of the
other ingredients of this medicine (listed in
section 6),
• if you are more than 3 months pregnant (It is also
better to avoid COZAAR in early pregnancy - see
Pregnancy),
• if your liver function is severely impaired,
• if you have diabetes or impaired kidney function
and you are treated with a blood pressure
lowering medicine containing aliskiren.
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before
taking COZAAR.
You must tell your doctor if you think you are
(or might become) pregnant. COZAAR is not
recommended in early pregnancy, and must not
be taken if you are more than 3 months pregnant,
as it may cause serious harm to your baby if used
at that stage (see pregnancy section).
It is important to tell your doctor before taking
COZAAR:
• if you have had a history of angiooedema
(swelling of the face, lips, throat, and/or tongue)
(see also section 4 ‘Possible side effects’),
• if you suffer from excessive vomiting or diarrhoea
leading to an extreme loss of fluid and/or salt
in your body,
• if you receive diuretics (medicines that increase
the amount of water that you pass out through
your kidneys) or are under dietary salt restriction
leading to an extreme loss of fluid and salt
in your body (see section 3 ‘Dosage in special
patient groups’),
• if you are known to have narrowing or blockage
of the blood vessels leading to your kidneys or if
you have received a kidney transplant recently,
• if your liver function is impaired (see sections 2
‘Do not take COZAAR’ and 3 ‘Dosage in special
patient groups’),
• if you suffer from heart failure with or without renal
impairment or concomitant severe life threatening
cardiac arrhythmias. Special caution is necessary
when you are treated with a ß‑blocker
concomitantly,
• if you have problems with your heart valves
or heart muscle,
• if you suffer from coronary heart disease (caused
by a reduced blood flow in the blood vessels of the
heart) or from cerebrovascular disease (caused
by a reduced blood circulation in the brain),
• if you suffer from primary hyperaldosteronism
(a syndrome associated with increased secretion
of the hormone aldosterone by the adrenal gland,
caused by an abnormality within the gland),
• if you are taking any of the following medicines
used to treat high blood pressure:
• an ACE-inhibitor (for example enalapril,
lisinopril, ramipril), in particular if you have
diabetes-related kidney problems.
• aliskiren
Your doctor may check your kidney function,
blood pressure, and the amount of electrolytes
(e.g. potassium) in your blood at regular intervals.
See also information under the heading “Do not
take COZAAR”.
Children and adolescents
COZAAR has been studied in children. For more
information, talk to your doctor.
COZAAR is not recommended for use in children
suffering from kidney or liver problems, as limited
data are available in these patient groups.
COZAAR is not recommended for use in children
under 6 years old, as it has not been shown
to work in this age group.
Other medicines and COZAAR
Tell your doctor or pharmacist if you are taking,
have recently taken, or might take any other
medicines.
Take particular care if you are taking the following
medicines while under treatment with COZAAR:
• other blood pressure lowering medicines as they
may additionally reduce your blood pressure.
Blood pressure may also be lowered by one of the
following drugs/ class of drugs: tricyclic
antidepressants, antipsychotics, baclofen,
amifostine,



medicines which retain potassium or may
increase potassium levels (e.g. potassium
supplements, potassium‑containing salt
substitutes or potassium‑sparing medicines
such as certain diuretics [amiloride, triamterene,
spironolactone] or heparin),
• non‑steroidal anti‑inflammatory drugs such
as indomethacin, including cox‑2‑inhibitors
(medicines that reduce inflammation, and can
be used to help relieve pain) as they may reduce
the blood pressure lowering effect of losartan.
Your doctor may need to change your dose and/or
to take other precautions:
If you are taking an ACE-inhibitor or aliskiren (see
also information under the headings “Do not take
COZAAR” and “Warnings and precautions”).
If your kidney function is impaired, the concomitant
use of these medicines may lead to a worsening of the
kidney function.
Lithium containing medicines should not be taken
in combination with losartan without close
supervision by your doctor. Special precautionary
measures (e.g. blood tests) may be appropriate.
COZAAR with food and drink
COZAAR may be taken with or without food.
Pregnancy and breast-feeding
Pregnancy
You must tell your doctor if you think you
are (or might become) pregnant. Your doctor
will normally advise you to stop taking COZAAR
before you become pregnant or as soon as you
know you are pregnant and will advise you to take
another medicine instead of COZAAR. COZAAR
is not recommended in early pregnancy, and must
not be taken when more than 3 months pregnant,
as it may cause serious harm to your baby if used
after the third month of pregnancy.
Breast-feeding
Tell your doctor if you are breast-feeding or about
to start breast-feeding. COZAAR is not recommended
for mothers who are breast-feeding, and your
doctor may choose another treatment for you
if you wish to breast-feed. Especially if your baby
is a newborn, or born prematurely.
Ask your doctor or pharmacist for advice before
taking this medicine.
Driving and using machines
No studies on the effects on the ability to drive
and use machines have been performed.
COZAAR is unlikely to affect your ability to drive
or use machines. However, as with many other
medicines used to treat high blood pressure, losartan
may cause dizziness or drowsiness in some people.
If you experience dizziness or drowsiness, you should
consult your doctor before attempting such activities.
COZAAR contains lactose
COZAAR contains lactose monohydrate. If you
have been told by your doctor that you have
an intolerance to some sugars, contact your doctor
before taking this medicine.
3. How to take COZAAR
Always take this medicine exactly as your doctor
or pharmacist has told you. Check with your doctor
or pharmacist if you are not sure. Your doctor
will decide on the appropriate dose of COZAAR,
depending on your condition and whether you are
taking other medicines. It is important to continue
taking COZAAR for as long as your doctor prescribes
it in order to maintain smooth control of your blood
pressure.
Adult patients with High Blood Pressure
Treatment usually starts with 50 mg losartan
(one tablet COZAAR 50 mg) once a day. The
maximal blood pressure lowering effect should
be reached 3‑6 weeks after beginning treatment.
In some patients the dose may later be increased
to 100 mg losartan
(two tablets
COZAAR 50 mg
or one tablet
of COZAAR 100 mg) once daily.
If you have the impression that the effect of losartan
is too strong or too weak, please talk to your doctor
or pharmacist.
Use in children and adolescents
Children below 6 years of age
COZAAR is not recommended for use in children
under 6 years old, as it has not been shown
to work in this age group.
Children aged 6 - 18 years old
The recommended starting dose in patients who
weigh between 20 and 50 kg is 0.7 mg of losartan
per kg of body weight administered once a day
(up to 25 mg of COZAAR). The doctor may increase
the dose if blood pressure is not controlled.
Other form(s) of this medicine may be more suitable
for children; ask your doctor or pharmacist.
Adult patients with high blood pressure and
Type 2 diabetes
Treatment usually starts with 50 mg losartan
(one tablet COZAAR 50 mg) once a day. The dose may
later be increased to 100 mg losartan (two tablets
COZAAR 50 mg or one tablet of COZAAR 100 mg)
once daily depending on your blood pressure response.
Losartan may be administered with other blood
pressure lowering medicines (e.g. diuretics,
calcium channel blockers, alpha‑ or beta‑blockers,
and centrally acting agents) as well as with insulin
and other commonly used medicines that decrease
the level of glucose in the blood (e.g. sulfonylureas,
glitazones and glucosidase inhibitors).
Adult patients with Heart Failure
Treatment usually starts with 12.5 mg losartan
(one tablet COZAAR 12.5 mg) once a day. Generally,
the dose should be increased weekly step‑by‑step
(i.e., 12.5 mg daily during the first week, 25 mg
daily during the second week, 50 mg daily
during the third week, 100 mg daily during
the fourth week, 150 mg daily during the fifth week)
up to the maintenance dose as determined by your
physician. A maximum dose of 150 mg losartan
(for example, three tablets of COZAAR 50 mg
or one tablet each of COZAAR 100 mg
and COZAAR 50 mg) once daily may be used.
In the treatment of heart failure, losartan is usually
combined with a diuretic (medicine that increases
the amount of water that you pass out through
your kidneys) and/or digitalis (medicine that helps
to make the heart stronger and more efficient)
and/or a beta‑blocker.
Dosage in special patient groups
The doctor may advise a lower dose, especially
when starting treatment in certain patients such
as those treated with diuretics in high doses,
in patients with liver impairment, or in patients
over the age of 75 years. The use of losartan is not
recommended in patients with severe hepatic
impairment (see section “Do not take COZAAR”).
Administration
The tablets should be swallowed whole with a glass
of water. You should try to take your daily dose
at about the same time each day. It is important
that you continue to take COZAAR until your doctor
tells you otherwise.
If you take more COZAAR than you should
If you accidentally take too many tablets, contact
your doctor immediately. Symptoms of overdose
are low blood pressure, increased heartbeat,
possibly decreased heartbeat.
If you forget to take COZAAR
If you accidentally miss a daily dose, just take the
next dose as normal. Do not take a double dose
to make up for a forgotten tablet. If you have any
further questions on the use of this medicine, ask
your doctor, pharmacist, or nurse.

For Position Only

For Position Only

XXXXXXX
XXXXXX-X
XXX
603392A01
N/A
N/A

XXXXXXX
XXXXXX-X
XXX
603392A01
N/A
N/A
XXXXXXX/XX-X

Black

Technical Info

Profile

AMS Blue Braille Grid Version: 38.0 - 24-11-17

4. Possible side effects
Like all medicines, this medicine can cause
side effects, although not everybody gets them.
If you experience the following, stop taking losartan
tablets and tell your doctor immediately or go
to the casualty department of your nearest hospital:
A severe allergic reaction (rash, itching, swelling of
the face, lips, mouth or throat that may cause
difficulty in swallowing or breathing).
This is a serious but rare side effect, which affects
more than 1 out of 10,000 patients but fewer
than 1 out of 1,000 patients. You may need urgent
medical attention or hospitalisation.
The following side effects have been reported
with COZAAR:
Common (may affect up to 1 in 10 people):
• dizziness,
• low blood pressure (especially after excessive
loss of water from the body within blood vessels
e.g. in patients with severe heart failure or under
treatment with high dose diuretics),
• dose‑related orthostatic effects such
as lowering of blood pressure appearing
when rising from a lying or sitting position,
• debility,
• fatigue,
• too little sugar in the blood (hypoglycaemia),
• too much potassium in the blood
(hyperkalaemia),
• changes in kidney function including kidney
failure,
• reduced number of red blood cells (anaemia),
• increase in blood urea, serum creatinine and
serum potassium in patients with heart failure.
Uncommon (may affect up to 1 in 100 people):
• somnolence,
• headache,
• sleep disorders,
• feeling of increased heart rate (palpitations),
• severe chest pain (angina pectoris),
• shortness of breath (dyspnoea),
• abdominal pain,
• obstipation,
• diarrhoea,
• nausea,
• vomiting,
• hives (urticaria),
• itching (pruritus),
• rash,
• localised swelling (oedema),
• cough.
Rare (may affect up to 1 in 1,000 people):
• hypersensitivity,
• angiooedema,
• inflammation of blood vessels (vasculitis
including Henoch‑Schönlein purpura),
• numbness or tingling sensation (paraesthesia),
• fainting (syncope),
• very rapid and irregular heartbeat (atrial
fibrillation),
• brain attack (stroke),
• inflammation of the liver (hepatitis),
• elevated blood alanine aminotransferase (ALT)
levels, usually resolved upon discontinuation
of treatment.
Not known (frequency cannot be estimated from the
available data):
• reduced number of thrombocytes,
• migraine,
• liver function abnormalities,
• muscle and joint pain,
• flu‑like symptoms,
• back pain and urinary tract infection,
• increased sensitivity to the sun
(photosensitivity),
• unexplained muscle pain with dark
(tea-coloured) urine (rhabdomyolysis),
• impotence,
• inflammation of the pancreas (pancreatitis),
• low levels of sodium in the blood (hyponatraemia),
• depression,
• generally feeling unwell (malaise),
• ringing, buzzing, roaring, or clicking in the ears
(tinnitus),
• disturbed taste (dysgeusia).
Side effects in children are similar to those seen
in adults.
Reporting of side effects
If you get any side effects, talk to your doctor,
pharmacist, or nurse. This includes any possible
side effects not listed in this leaflet. You can also
report side effects directly (see details below).
By reporting side effects you can help provide more
information on the safety of this medicine.
United Kingdom: Yellow Card Scheme Website:
www.mhra.gov.uk/yellowcard or search for MHRA
Yellow Card in the Google Play or Apple App Store
Malta: ADR Reporting Website:
www.medicinesauthority.gov.mt/adrportal
5. How to store COZAAR
Keep this medicine out of the sight and reach
of children.
Do not use this medicine after the expiry date
which is stated on the carton or the bottle label.
The expiry date refers to the last day of that month.
Blisters:
Store COZAAR in the original package in order
to protect from light and moisture.
Do not open the blister pack until you are ready
to take the medicine.
Bottles:
Store COZAAR in the original container in order
to protect from light.
Do not store above 25°C. Keep the bottle tightly
closed in order to protect from moisture.
Do not throw away any medicines via wastewater or
household waste. Ask your pharmacist how to throw
away medicines you no longer use. These measures
will help protect the environment.

Profile:
Profile Revision:
Profile Revision Date:
Dimensions (mm):

BG148x520_260
7
050708
148 x 520mm

6. Contents of the pack and other information
What COZAAR contains
The active substance is losartan potassium.
Each COZAAR 12.5 mg tablet contains 12.5 mg
of losartan potassium.
Each COZAAR 25 mg tablet contains 25 mg
of losartan potassium.
Each COZAAR 50 mg tablet contains 50 mg
of losartan potassium.
Each COZAAR 100 mg tablet contains 100 mg
of losartan potassium.
The other ingredients are microcrystalline cellulose
(E460), lactose monohydrate, pregelatinized maize
starch, magnesium stearate (E572), hyprolose (E463),
hypromellose (E464).
COZAAR 12.5 mg, 25 mg, 50 mg and 100 mg
contain potassium in the following amounts:
1.06 mg (0.027 mEq), 2.12 mg (0.054 mEq), 4.24 mg
(0.108 mEq) and 8.48 mg (0.216 mEq) respectively.
The COZAAR 12.5 mg tablets also contain carnauba
wax (E903), titanium dioxide (E171) and indigo
carmine (E132) aluminum lake.
The COZAAR 25 mg tablets also contain carnauba
wax (E903) and titanium dioxide (E171).
The COZAAR 50 mg tablets also contain carnauba
wax (E903) and titanium dioxide (E171).
The COZAAR 100 mg tablets also contain carnauba
wax (E903) and titanium dioxide (E171).
What COZAAR looks like and contents of the pack
COZAAR 12.5 mg is supplied as unscored film‑coated
tablets containing 12.5 mg of losartan potassium.
COZAAR 25 mg, is supplied as unscored film‑coated
tablets containing 25 mg of losartan potassium.

COZAAR 50 mg is supplied as scored film‑coated
tablets containing 50 mg of losartan potassium. The
score line is not intended for breaking the tablet.
COZAAR 100 mg is supplied as unscored film‑coated
tablets containing 100 mg of losartan potassium.
COZAAR is supplied in the following pack sizes:
• COZAAR 12.5 mg ‑ PVC/PE/PVDC blister
packages with aluminum foil lidding in packs
of 7, 14, 21, 28, 50, 98, 210 or 500 tablets
and a unit-dose package of 28 tablets for
hospital use. HDPE bottles of 100 tablets.
• COZAAR 25 mg - PVC/PE/PVDC blister
packages with aluminum foil lidding in packs
of 7 or 28 tablets.
• COZAAR 50 mg - PVC/PE/PVDC blister packages
with aluminum foil lidding in packs of 7, 10, 14,
20, 28, 30, 50, 56, 84, 90, 98, 280 or 500 tablets
and unit-dose packages of 28, 56 and 98 tablets
for hospital use. HDPE bottles
of 100 or 300 tablets.
• COZAAR 100 mg - PVC/PE/PVDC blister
packages with aluminum foil lidding in packs
of 7, 10, 14, 15, 20, 28, 30, 50, 56, 84, 90, 98
or 280 tablets and unit-dose packages
of 28, 56 and 98 tablets for hospital use. HDPE
bottles of 100 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder:
Merck Sharp & Dohme Limited, Hertford Road,
Hoddesdon, Hertfordshire, EN11 9BU, UK.
Manufacturer:
12.5 mg: Merck Sharp & Dohme BV/MMD,
Waarderweg 39, 2031 BN, Haarlem, Netherlands.
25 mg, 50 mg and 100 mg: Merck Manufacturing
Division, Merck Sharp & Dohme Limited, Shotton
Lane, Cramlington, Northumberland, NE23 3JU, UK.
This medicinal product is authorised in the Member
States of the EEA under the following names:
Member State
Invented name
Austria
Cosaar 12,5 mg - Filmtabletten
Austria
Cosaar 50 mg - Filmtabletten
Austria
Cosaar 100 mg - Filmtabletten
Belgium
COZAAR 12,5 mg
Belgium
COZAAR 50 mg
Belgium
COZAAR 100 mg
Bulgaria
COZAAR 12,5 mg film-coated
tablets
Bulgaria
COZAAR 50 mg film-coated
tablets
Cyprus
COZAAR
Czech Republic
COZAAR 50 mg
Czech Republic
COZAAR 100 mg
Denmark
Cozaar
Finland
Cozaar 12,5 mg
kalvopäällysteiset tabletit
Finland
Cozaar 50 mg kalvopäällysteiset
tabletit
Finland
Cozaar 100 mg
kalvopäällysteiset tabletit
France
COZAAR 50 mg scored coated
tablets
France
COZAAR 100 mg film-coated
tablets
Germany
LORZAAR PROTECT 100 mg
Filmtabletten
Germany
LORZAAR PROTECT 50 mg
Filmtabletten
Germany
LORZAAR START 12,5 mg
Filmtabletten
Greece
COZAAR
Hungary
COZAAR
Iceland
COZAAR
Ireland
COZAAR 12.5mg film-coated
tablets
Ireland
COZAAR 50 mg film-coated
tablets
Ireland
COZAAR 100 mg film-coated
tablets
Italy
LORTAAN 12,5 mg compresse
rivestite con film
Italy
LORTAAN 50 mg compresse
rivestite con film
Italy
LORTAAN 100 mg compresse
rivestite con film
Luxembourg
COZAAR 12,5 mg
Luxembourg
COZAAR 50 mg
Luxembourg
COZAAR 100 mg
Malta
COZAAR 12,5 mg film-coated
tablets
Malta
COZAAR 50 mg film-coated
tablets
Malta
COZAAR 100 mg film-coated
tablets
Netherlands
COZAAR 12,5 mg
Netherlands
COZAAR 50 mg
Netherlands
COZAAR 100 mg
Norway
Cozaar
Poland
COZAAR
Portugal
Cozaar
Portugal
Cozaar 100 mg
Portugal
Cozaar IC
Romania
COZAAR 12,5 mg comprimate
filmate
Romania
COZAAR 50 mg comprimate
filmate
Slovenia
Cozaar 12,5 mg filmsko
obložene tablete
Slovenia
Cozaar 50 mg filmsko obložene
tablete
Slovenia
Cozaar 100 mg filmsko obložene
tablete
Spain
COZAAR 12,5 mg Inicio
comprimidos recubiertos con
película
Spain
COZAAR 50 mg comprimidos
recubiertos con película
Spain
COZAAR 100 mg comprimidos
recubiertos con película
Sweden
COZAAR 12,5 mg filmdragerade
tabletter
Sweden
COZAAR 50 mg filmdragerade
tabletter
Sweden
COZAAR 100 mg filmdragerade
tabletter
United Kingdom COZAAR 12,5 mg film-coated
tablets
United Kingdom COZAAR 25 mg film-coated
tablets
United Kingdom COZAAR 50 mg film-coated
tablets
United Kingdom COZAAR 100 mg film-coated
tablets
This leaflet was last revised in December 2017
PIL.CZR.17.UK.6185.IB-040
© Merck Sharp & Dohme Limited 2017. All rights
reserved.

+ Expand Transcript

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide